Latest News & Features
Big Pharma
EPO case law suggests that inventions covering homeopathic medicines do not have to meet a higher bar of patentability than conventional medicaments, but it still must be shown that the claimed products lead to the alleged therapeutic effect. André Guder of Uexküll & Stolberg reports. 7 June 2016
Americas
Applicants wishing to extend their patents’ term of protection do not have to necessarily match up the wording of the claims and the label of the relevant drug for there to be infringement by an ANDA, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports. 7 June 2016
Americas
Pharmaceutical company AstraZeneca has agreed a licensing deal with German drug maker Grünenthal centring on gout treatment drug Zurampic. 6 June 2016
Big Pharma
Europe is not providing an adequate level of patent protection to the medical device industry, and while a solution exists, legislators need to be brave enough to abandon convention and adopt it, argue Reuben Jacob and Fiona Kellas of Jenkins. 6 June 2016
Asia
Over the past few years there have been a number of IP developments in the pharma and biotech industries in Japan, including on patent term extension and product-by-process claims. Osamu Yamamoto of Yuasa and Hara provides a roundup. 6 June 2016
article
More than 15,000 life sciences industry professionals will arrive in San Francisco for the 2016 BIO International Convention from June 6 to 9. LSIPR highlights some of the most interesting sessions 6 June 2016
Americas
If you can find the time between attending sessions and networking, making the most of the local area is an essential part of the 2016 BIO International Convention. LSIPR offers five tips for things to see and do in San Francisco. 6 June 2016
Americas
In an interview with LSIPR, Hans Sauer, deputy general counsel for intellectual property at the Biotechnology Innovation Organization, explains more about the big issues affecting it at the moment and how the trade association is responding. 6 June 2016
Biotechnology
Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR. 5 June 2016
Biotechnology
The biotech industry on both sides of the Atlantic is facing serious challenges in protecting its inventions, argues Nathalie Moll, secretary general of EuropaBio, which is organising a discussion on the topic at the 2016 BIO International Convention in San Francisco. 5 June 2016